新生儿感染口服抗生素的系统综述与荟萃分析
该系统综述与荟萃分析评估了新生儿(0-28天)使用口服抗生素及口服转换治疗的药代动力学、安全性和有效性。疗效研究显示复发率(OR 0.95;95% CI 0.79-1.16;I2 0%)和死亡率(OR 1.11;95% CI 0.72-1.72;I2 0%)与静脉给药相当,且住院时间缩短。结论认为早期口服转换治疗可能有益,但需更多设计良好的试验。
要点
- 新生儿口服抗生素多数可达有效血药浓度,但达峰较晚、生物利用度较低。
- 口服与静脉给药相比,复发率和死亡率无显著差异,且住院时间缩短。
- 现有证据有限,需更多设计良好的试验评估临床有效性和安全性。
核心结论
- 新生儿口服抗生素可被吸收并在多数情况下达到对相关病原体MIC的有效血清水平。
- 疗效研究显示口服抗生素的复发率(OR 0.95;95% CI 0.79-1.16;I2 0%)和死亡率(OR 1.11;95% CI 0.72-1.72;I2 0%)与静脉给药相当,且住院时间缩短。
- 早期口服抗生素转换治疗可能对家庭和医疗系统均有益,但缺乏稳健证据,需更多设计良好的试验。
研究设计与样本
- 系统检索Medline、Embase.com、Cochrane、Google Scholar和Web of Science。
- 纳入标准为描述新生儿(0-28天)使用口服抗生素的研究,包括抗生素转换研究和药理学研究。
主要发现
- 与肠外给药相比,口服抗生素通常达峰时间更晚且生物利用度更低,但多数情况下可达足以杀灭细菌的血清水平。
- 疗效研究显示口服抗生素的复发率(OR 0.95;95% CI 0.79-1.16;I2 0%)或死亡率(OR 1.11;95% CI 0.72-1.72;I2 0%)与肠外给药相比无显著差异。
- 观察到住院时间缩短。
临床怎么用
- 新生儿口服抗生素可作为静脉治疗的潜在替代方案,尤其适用于早期转换治疗。
- 临床决策时应考虑口服抗生素达峰较晚和生物利用度较低的特点。
- 早期口服转换治疗可能缩短住院时间,对家庭和医疗系统有益。
局限性
- 许多研究中临床有效性和安全性未得到充分评估,缺乏稳健证据。
- 需要在不同环境下开展更多设计良好的试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Worldwide many neonates suffer from bacterial infections. Adequate treatment is important but is associated with prolonged hospitalization for intravenous administration. In older children, oral switch therapy has been proven effective and safe for several indications and is now standard care. OBJECTIVES: To evaluate the currently available evidence on pharmacokinetics, safety and efficacy of oral antibiotics and oral switch therapy in neonates (0-28 days old). METHODS: We performed systematic searches in Medline, Embase.com, Cochrane, Google Scholar and Web of Science. Studies were eligible if they described the use of oral antibiotics in neonates (0-28 days old), including antibiotic switch studies and pharmacological studies. RESULTS: Thirty-one studies met the inclusion criteria. Compared with parenteral administration, oral antibiotics generally reach their maximum concentration later and have a lower bioavailability, but in the majority of cases adequate serum levels for bacterial killing are reached. Furthermore, studies on efficacy of oral antibiotics showed equal relapse rates (OR 0.95; 95% CI 0.79-1.16; I2 0%) or mortality (OR 1.11; 95% CI 0.72-1.72; I2 0%). Moreover, a reduction in hospital stay was observed. CONCLUSIONS: Oral antibiotics administered to neonates are absorbed and result in adequate serum levels, judged by MICs of relevant pathogens, over time. Efficacy studies are promising but robust evidence is lacking, most importantly because in many cases clinical efficacy and safety are not properly addressed. Early oral antibiotic switch therapy in neonates could be beneficial for both families and healthcare systems. There is a need for additional well-designed trials in different settings.
引用
- Keij FM, Kornelisse RF, Hartwig NG, et al. Oral antibiotics for neonatal infections: a systematic review and meta-analysis. J Antimicrob Chemother. 2019. PMID: 31236572. doi:10.1093/jac/dkz252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。